Clinical trialNCT05329194CompletedPhase 4Interventional

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

SponsorAstraZenecaEnrollment286Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Njira Lugogo., MD.
University of Michigan Health. Michigan, USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Research Site
Mobile, Alabama, United States
Research Site
Gilbert, Arizona, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Rancho Mirage, California, United States
Research Site
Westminster, California, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
New Haven, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Chicago, Illinois, United States
Research Site
Lexington, Kentucky, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Upper Marlboro, Maryland, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Ypsilanti, Michigan, United States
Research Site
Saint Paul, Minnesota, United States
Research Site
St Louis, Missouri, United States
Research Site
Lincoln, Nebraska, United States
Research Site
Omaha, Nebraska, United States
Research Site
Hollis, New York, United States
Research Site
Horseheads, New York, United States
Research Site
Rochester, New York, United States
Research Site
Valhalla, New York, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Wilmington, North Carolina, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Altoona, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Warwick, Rhode Island, United States
Research Site
Greenville, South Carolina, United States
Research Site
Hendersonville, Tennessee, United States
Research Site
Fort Worth, Texas, United States
Research Site
McKinney, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Charlottesville, Virginia, United States
Research Site
Vancouver, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tezepelumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Apr 2022
Primary completion: 1 Oct 2025
Completion: 1 Oct 2025
Last update posted: 16 Jul 2026
Registered enrollment: 286
Registry id: NCT05329194

Cross-registrations

EU-CTR / CTIS (EudraCT)2026-000081-25

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.